XTX Topco Ltd Invests $5.96 Million in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Key Points

• XTX Topco Ltd has acquired 12,027 shares of Intuitive Surgical, Inc., valued at approximately $5.96 million, making it the fund's 27th largest holding.
• Insider trades include Jami K. Nachtsheim selling 2,400 shares for $1.25 million, reducing his ownership by 27.36%.
• According to various analysts, Intuitive Surgical has a "Moderate Buy" average rating, with price targets ranging from $550 to $650, reflecting expected growth in the company's stock performance.

XTX Topco Ltd acquired a new position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 12,027 shares of the medical equipment provider's stock, valued at approximately $5,957,000. Intuitive Surgical comprises approximately 0.3% of XTX Topco Ltd's portfolio, making the stock its 27th largest position.

Other hedge funds and other institutional investors have also modified their holdings of the company. Hurley Capital LLC acquired a new stake in Intuitive Surgical during the fourth quarter worth $28,000. Parvin Asset Management LLC acquired a new stake in Intuitive Surgical during the fourth quarter worth $26,000. Chilton Capital Management LLC boosted its stake in Intuitive Surgical by 614.3% during the first quarter. Chilton Capital Management LLC now owns 50 shares of the medical equipment provider's stock worth $25,000 after buying an additional 43 shares in the last quarter. Global Financial Private Client LLC boosted its stake in Intuitive Surgical by 253.3% during the first quarter. Global Financial Private Client LLC now owns 53 shares of the medical equipment provider's stock worth $26,000 after buying an additional 38 shares in the last quarter. Finally, Elite Financial Inc. acquired a new stake in Intuitive Surgical during the first quarter worth $26,000. Institutional investors and hedge funds own 83.64% of the company's stock.

Analysts Set New Price Targets

A number of research firms have weighed in on ISRG. Wall Street Zen upgraded shares of Intuitive Surgical from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Truist Financial lifted their price target on shares of Intuitive Surgical from $590.00 to $600.00 and gave the stock a "buy" rating in a research note on Wednesday, July 23rd. Royal Bank Of Canada lifted their price objective on Intuitive Surgical from $605.00 to $615.00 and gave the company an "outperform" rating in a report on Wednesday, July 23rd. Evercore ISI lifted their price objective on Intuitive Surgical from $470.00 to $550.00 and gave the company an "in-line" rating in a report on Tuesday, July 8th. Finally, Deutsche Bank Aktiengesellschaft cut Intuitive Surgical from a "hold" rating to a "sell" rating and cut their price objective for the company from $515.00 to $440.00 in a report on Monday, June 9th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and fifteen have given a buy rating to the stock. According to MarketBeat.com, Intuitive Surgical currently has a consensus rating of "Moderate Buy" and an average price target of $592.05.

Intuitive Surgical Stock Up 0.4%

ISRG stock traded up $2.03 during midday trading on Friday, reaching $483.12. The stock had a trading volume of 2,982,876 shares, compared to its average volume of 1,997,437. The business has a fifty day simple moving average of $524.01 and a two-hundred day simple moving average of $533.35. The firm has a market cap of $173.19 billion, a price-to-earnings ratio of 67.38, a PEG ratio of 5.04 and a beta of 1.60. Intuitive Surgical, Inc. has a twelve month low of $425.00 and a twelve month high of $616.00.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, topping analysts' consensus estimates of $1.93 by $0.26. The firm had revenue of $2.44 billion during the quarter, compared to analyst estimates of $2.35 billion. Intuitive Surgical had a return on equity of 14.56% and a net margin of 28.51%. The company's revenue was up 21.4% on a year-over-year basis. During the same period last year, the company earned $1.78 earnings per share. On average, equities analysts predict that Intuitive Surgical, Inc. will post 6.43 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, SVP Mark Brosius sold 216 shares of the business's stock in a transaction dated Friday, June 6th. The stock was sold at an average price of $563.11, for a total transaction of $121,631.76. Following the completion of the transaction, the senior vice president directly owned 907 shares in the company, valued at approximately $510,740.77. The trade was a 19.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Myriam Curet sold 4,500 shares of the business's stock in a transaction dated Friday, July 25th. The stock was sold at an average price of $492.48, for a total value of $2,216,160.00. Following the transaction, the executive vice president owned 353 shares of the company's stock, valued at $173,845.44. The trade was a 92.73% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 15,903 shares of company stock worth $7,932,778 over the last three months. 0.70% of the stock is currently owned by company insiders.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.